Joseph Thome

Q: How accurate are Joseph Thome's stock ratings?

About 51% of Joseph's ratings were profitable over a one-year hold, with an average return of +2.9% per rating, measured by 13Foresight from historical prices.

Q: How is Joseph ranked?

Joseph Thome is ranked #2023 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

TD Cowen

Wall Street Analyst

★★★☆☆

#2023

on 13Foresight · ranked by our own returns

51%

Success Rate

+2.9%

Average Return

23 of 45 calls profitable · -2.5% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 51% of Joseph Thome's ratings turned a profit when each position was held for 1 year — averaging +2.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

143 Buy 8 Hold 0 Sell

Joseph's Stock Coverage 29 ratings · 2026-08-05

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
JAZZ Jazz Pharmaceuticals	Aug 04, 2026	BUY	Strong Buy -9.3% avg upside 35 analysts	$300.00 14.62% Upside	+0.0%	·
ARWR Arrowhead Pharmaceuticals	Aug 04, 2026	BUY	Strong Buy -17.1% avg upside 27 analysts	—	·	·
PTCT PTC Therapeutics	Jul 30, 2026	BUY	Buy +17.6% avg upside 29 analysts	$90.00 30.27% Upside	-8.5%	·
QURE uniQure	Jul 29, 2026	BUY	Strong Buy +34.9% avg upside 29 analysts	—	+8.7%	·
ALKS Alkermes	Jul 28, 2026	BUY	Strong Buy -16.3% avg upside 34 analysts	$58.00 16.76% Upside	-3.0%	·
DYN Dyne Therapeutics	Jul 28, 2026	BUY	Strong Buy +54.9% avg upside 31 analysts	—	-2.8%	·
RAPP Rapport Therapeutics, Inc.	Jul 17, 2026	BUY	Strong Buy +31.0% avg upside 14 analysts	—	-4.3%	·
ANAB AnaptysBio	Jul 13, 2026	BUY	Strong Buy +32.2% avg upside 26 analysts	$75.00 35.96% Upside	-20.9%	·
AXSM Axsome Therapeutics	Jun 16, 2026	BUY	Strong Buy +9.5% avg upside 29 analysts	$300.00 41.46% Upside	+0.1%	·
NTLA Intellia Therapeutics	Jun 14, 2026	BUY	Buy +245.8% avg upside 37 analysts	—	-25.3%	·
NGEN NervGen Pharma	Jun 11, 2026	BUY	Strong Buy +482.6% avg upside 9 analysts	—	-15.3%	·
UTHR United Therapeutics	Jun 05, 2026	BUY	Buy -16.2% avg upside 26 analysts	$675.00 30.07% Upside	-5.6%	·
DRUG Bright Minds Biosciences	May 20, 2026	BUY	Strong Buy +72.8% avg upside 10 analysts	—	-13.0%	·
MPLT MapLight Therapeutics, Inc.	May 14, 2026	BUY	Strong Buy +174.4% avg upside 13 analysts	—	-55.5%	·
MGX Metagenomi, Inc.	May 11, 2026	BUY	Strong Buy +624.3% avg upside 8 analysts	—	-11.8%	·
DNLI Denali Therapeutics	May 08, 2026	BUY	Strong Buy +56.6% avg upside 24 analysts	—	+23.2%	·
XENE Xenon	May 07, 2026	BUY	Strong Buy -1.5% avg upside 28 analysts	—	+11.2%	·
PRME Prime Medicine, Inc.	May 07, 2026	BUY	Strong Buy +237.9% avg upside 16 analysts	—	-4.5%	·
TRDA Entrada Therapeutics Inc	May 07, 2026	BUY	Strong Buy +194.0% avg upside 10 analysts	—	+5.7%	·
MIRM Mirum Pharmaceuticals	May 07, 2026	BUY	Strong Buy +12.8% avg upside 22 analysts	$145.00 38.93% Upside	+2.3%	·
VRDN Viridian Therapeutics	May 05, 2026	BUY	Strong Buy +72.4% avg upside 32 analysts	—	+10.1%	·
AMLX Amylyx Pharmaceuticals Inc	May 05, 2026	BUY	Strong Buy +21.1% avg upside 14 analysts	—	+33.0%	·
ARDX Ardelyx	Apr 30, 2026	BUY	Strong Buy +179.2% avg upside 21 analysts	$13.00 159.55% Upside	-21.8%	·
MCRB Seres Therapeutics	Nov 05, 2025	BUY	Buy +220.2% avg upside 11 analysts	—	-62.4%	·
JBIO Jade Biosciences	Jul 19, 2024	HOLD	Strong Buy +180.5% avg upside 16 analysts	—	-84.4%	·
EVLO Evelo Biosciences	Oct 17, 2023	HOLD	Buy +3752499900.0% avg upside 5 analysts	—	·	·
PTC PTC	May 24, 2023	HOLD	Strong Buy +3.3% avg upside 31 analysts	$40.00 71.82% Downside	+40.4%	·
HLIT Harmonic	Oct 10, 2022	BUY	Buy +5.8% avg upside 14 analysts	—	-30.5%	·
PVLA Palvella Therapeutics	Oct 01, 2020	BUY	Strong Buy +12.1% avg upside 27 analysts	—	+151.7%	·

🔒 24 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Joseph Thome — Frequently Asked Questions

How accurate are Joseph Thome's stock ratings?

Based on the calls 13Foresight could measure, about 51% of Joseph's ratings were profitable over a one-year hold, with an average return of +2.9% per rating, or -2.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Joseph ranked on 13Foresight?

Joseph Thome is currently ranked #2023 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Joseph cover?

Joseph most recently has ratings on JAZZ, ARWR, PTCT, QURE, ALKS, DYN, RAPP, ANAB, AXSM, NTLA, NGEN, UTHR and 17 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Joseph Thome

Rating Distribution

Welcome to 13Foresight!